{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T03:27:49Z","timestamp":1761881269475,"version":"build-2065373602"},"reference-count":11,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Medicina Intensiva (English Edition)"],"published-print":{"date-parts":[[2022,6]]},"DOI":"10.1016\/j.medine.2021.05.007","type":"journal-article","created":{"date-parts":[[2022,6,7]],"date-time":"2022-06-07T11:39:32Z","timestamp":1654601972000},"page":"348-350","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Ceftaroline versus standard therapy for pneumococcal meningitis in critically ill patients"],"prefix":"10.1016","volume":"46","author":[{"given":"M.","family":"Mart\u00edn-Cerezuela","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.\u00ff.","family":"Padr\u00f3s Olmedo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.P.","family":"Piqueres","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.B.","family":"de Pedro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.F.","family":"Art\u00e9s","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.R.","family":"Galleymore","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.medine.2021.05.007_bib0060","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.ijid.2013.09.012","article-title":"Mortality indicators in pneumococcal meningitis: Therapeutic implications","volume":"19","author":"Erdem","year":"2014","journal-title":"Int J Infect Dis"},{"key":"10.1016\/j.medine.2021.05.007_bib0065","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/S1473-3099(15)00430-2","article-title":"Community-acquired bacterial meningitis in adults in the Netherlands, 2006-14: a prospective cohort study","volume":"16","author":"Bijlsma","year":"2016","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.medine.2021.05.007_bib0070","first-page":"19","article-title":"FOCUS 1 a randomized, double-blinded, multicentre, Phase III trial of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in community-acquired pneumonia","volume":"3","author":"File","year":"2011","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.medine.2021.05.007_bib0075","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1093\/jac\/dkr097","article-title":"FOCUS 2 a randomized, double-blinded, multicentre, Phase III trial of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in community-acquired pneumonia","volume":"3","author":"Low","year":"2011","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.medine.2021.05.007_bib0080","doi-asserted-by":"crossref","first-page":"5808","DOI":"10.1128\/AAC.00285-13","article-title":"Efficacy of ceftaroline fosamil against Escherichia coli and Klebsiella pneumoniae strains in a rabbit meningitis model","volume":"57","author":"Stucki","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.medine.2021.05.007_bib0085","doi-asserted-by":"crossref","first-page":"2428","DOI":"10.1128\/AAC.04965-14","article-title":"Examining the use of ceftaroline in the treatment of streptococcus pneumoniae meningitis with reference to human cathelicidin LL-37","volume":"59","author":"Sakoulas","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.medine.2021.05.007_bib0090","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1007\/s40265-017-0785-2","article-title":"Early use of ceftaroline fosamil in the united states veterans health care system","volume":"77","author":"Britt","year":"2017","journal-title":"Drugs"},{"key":"10.1016\/j.medine.2021.05.007_bib0095","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/S0213-005X(14)70153-3","article-title":"Farmacocin\u00e9tica y farmacodinamia de ceftarolina","volume":"32","author":"Grau","year":"2014","journal-title":"Enferm Infecc Microbiol Clin"},{"key":"10.1016\/j.medine.2021.05.007_bib0100","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1086\/425368","article-title":"Practice guidelines for the management of bacterial meningitis","volume":"39","author":"Tunkel","year":"2004","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.medine.2021.05.007_bib0105","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.cmi.2016.01.007","article-title":"ESCMID guideline: diagnosis and treatment of acute bacterial meningitis","volume":"22","author":"van de Beek","year":"2016","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.medine.2021.05.007_bib0110","first-page":"634","article-title":"High-dose ceftriaxone for bacterial meningitis and optimization of administration scheme based on nomogram","volume":"23","author":"Gr\u00e9goire","year":"2019","journal-title":"Antimicrob Agents Chemother"}],"container-title":["Medicina Intensiva (English Edition)"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2173572722001059?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2173572722001059?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T02:35:10Z","timestamp":1761878110000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2173572722001059"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6]]},"references-count":11,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2022,6]]}},"alternative-id":["S2173572722001059"],"URL":"https:\/\/doi.org\/10.1016\/j.medine.2021.05.007","relation":{},"ISSN":["2173-5727"],"issn-type":[{"type":"print","value":"2173-5727"}],"subject":[],"published":{"date-parts":[[2022,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Ceftaroline versus standard therapy for pneumococcal meningitis in critically ill patients","name":"articletitle","label":"Article Title"},{"value":"Medicina Intensiva (English Edition)","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.medine.2021.05.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Espa\u00f1a,  S.L.U. and SEMICYUC. All rights reserved.","name":"copyright","label":"Copyright"}]}}